Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).Mark J. Levis, Erkut Bahceci, Ellen K. Ritchie et al.|Journal of Clinical Oncology|2015Cited by 39
Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response StudyJessica K. Altman, Erkut Bahceci, Alexander E. Perl et al.|Blood|2015Cited by 29